CD57 (Natural Killer Cell Marker) Ab-2 (Clone HNK-1) 

Mouse Monoclonal Antibody 

Cat. #MS-1163-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide) 
Cat. #MS-1163-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide) 
Cat. #MS-1163-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining) 
Cat. #MS-1163-PCS (5 Slides) (Positive Control for Histology) 

Description: 
CD57/HNK-1 is expressed on a subpopulation of 15-20% of peripheral blood mononuclear cells, about 60% of NK active cells and on a subset of T cells. 

Comments: 
Ab-2 marks a subset of lymphocytes known as natural killer (NK) cells. Ab-2 reportedly also reacts with a variety of cell types in non-lymphoid tissues. Ab-2 stains neuroendocrine cells and their tumors. NEOMARKERS’ Ab-2 (clone HNK-1) and Ab-3 (clone VC1.1) inhibit the binding of each other. 

Mol. Wt. of Antigen: 110kDa 
Species Reactivity: Human. Others-not known. 
Clone Designation: HNK-1 (same as Leu-7) 
Ig Isotype / Light Chain: IgM / κ 
Immunogen: Membrane extracts of the HSB-2 T lymphoblastoid cell line. 

Applications and Suggested Dilutions: 
• Flow Cytometry 
• Immunohistology (Formalin/paraffin) 
  (Ab 2-4µg/ml for 30 min at RT) 
  * (No special pretreatment is required for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues) 

The optimal dilution for a specific application should be determined by the investigator. 

Positive Control: Lymph node or tonsil 
Cellular Localization: Cell membrane 

Storage and Stability: 
Ab with sodium azide is stable for 24 months when stored at 2-8°C. Antibody WITHOUT sodium azide is stable for 36 months when stored at below 0°C. 

Supplied As: 
200µg/ml antibody purified from the ascites fluid by ammonium sulfate precipitation and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. Also available without BSA and azide at 1mg/ml. 

or 
Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues. 

Key References: 

Limitations and Warranty: 
Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. NeoMarkers is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. 

Material Safety Data: 
This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes. 

For Research Use Only
Additional Key References:


12. Pandolfi D; Loughran TP Jr; Starkebaum G; Chisesi T; Barbi T; Chan WC; Brouet JC; De Rossi G; McKinna RW; Salsano F; et al. Clinical course and prognosis of the lymphoproliferative disorder of granular lymphocytes. A multicenter study. Cancer, 1990, 65(2):341-8.


17. Mukhopadhyaya R; Tatake RJ; Khilnani N; Rao RS; Fakih AR; Naik SL; Gangal SG. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients. Journal of Clinical and Laboratory Immunology, 1989, 30(1):21-5.


25. Herait P; Ganem G; Lipinski M; Carlu C; Micheau C; Poupon RE; Baru M; Baudin E; Turc-Carel C; El Mestikawy S; Ropars L; Pompon B; Coullier P; Vital C; Schalch J; De-Montmollin FE; Bossuyt P; Esteve J; Basset Y; Tran Y; Schwaab G; De-The G; Tursz T. Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of B cell markers.
CD57 (Natural Killer Cell Marker) Ab-2 (Clone HNK-1) 
Mouse Monoclonal Antibody
Cat. #MS-1163-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 200 µg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-1163-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)
Cat. #MS-1163-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-1163-PCS (5 Slides) (Positive Control for Histology)

29. Fujimiya Y; Vender A; Chang WC; Linker-Israeli M; Udis B; Horwitz D; Pattengale PK. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1. International Journal of Cancer, 1986, 37(5):639-49.
31. Kodama T; Watanabe S; Sato Y; Shimosato Y; Miyazawa N. An immunohistochemical study of thymic epithelial tumors. I. Epithelial component. American Journal of Surgical Pathology, 1986, 10(1):26-33..
50. Swerdlow SH; Habeshaw JA; Richards MA; Rainey M; Murray LJ; Stansfeld AG. T lymphoblastic lymphoma with LEU-7 positive phenotype and unusual clinical course: a multiparameter study. Leukemia Research, 1985, 9(1):167-73.
51. Wahab ZA; Wright GL Jr. Monoclonal antibody (anti-Leu-7) directed against natural killer cells reacts with normal, benign
CD57 (Natural Killer Cell Marker) Ab-2 (Clone HNK-1)

Mouse Monoclonal Antibody
Cat. #MS-1163-P0, -P1, or -P (0.1ml, 0.5ml, or 1.0ml at 200 µg/ml) (Purified Ab with BSA and Azide)
Cat. #MS-1163-P1ABX or -PABX (0.1ml or 0.2ml at 1.0mg/ml)
Cat. #MS-1163-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)
Cat. #MS-1163-PCS (5 Slides) (Positive Control for Histology)

32. Abo T; Miller CA; Balch CM. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults. European Journal of Immunology, 1984, 14(7):616-23.
34. Caillaud JM; Benjelloun S; Bosq J; Graham K; Lipinski M. HNK-1-defined antigen detected in paraffin-embedded neuroectodermal tumors and those derived from cells of the amine precursor uptake and decarboxylation system. Cancer Research, 1984, 44(10):4322-3.
36. Kruse J; Mailhammer R; Wernecke H; Faisstner A; Sommer I; Goridis C; Schachner M. Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. Nature, 1984, 311(5982):153-5.
37. Manara GC; de Panfilis G; Ferrari C; Bonati A; Scandroglio R. The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. Histochemistry, 1984, 81(2):153-5.
42. Tucker GC; Aoyama H; Lipinski M; Tursz T; Thiery JP. Identical reactivity of monoclonal antibodies HNK-1 and NC-1: conservation in vertebrates on cells derived from the neural primordium and on some leukocytes. Cell Differentiation, 1984, 14(3):223-30.
44. Lanier LL; Le AM; Phillips JH; Warner NL; Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. Journal of Immunology, 1983, 131(4):1789-96.
45. Lipinski M; Graham K; Caillaud JM; Carlu C; Tursz T. HNK-1 antibody detects an antigen expressed on neuroectodermal cells. Journal of Experimental Medicine, 1983 1, 158(5):1775-80.
47. Mori S; Mohri N; Morita H; Yamaguchi K; Shimamine T. The distribution of cells expressing a natural killer cell marker (HNK-1) in normal human lymphoid organs and malignant lymphomas. Virchows Archiv. B. Cell Pathology, 1983, 43:253-63.